Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
News Releases

News Releases

Date Title and Summary
Toggle Summary Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
- XIENCE Sierra™, the newest generation of XIENCE drug-eluting stents, received U.S. Food and Drug Administration (FDA) approval - XIENCE stents are among the most-widely used and studied stents in the world and have an unparalleled safety record - New features help doctors treat more
Toggle Summary Abbott's Investigational Tendyne™ Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study
- Promising results for Tendyne valve presented as late-breaking clinical trial at EuroPCR - Early data showed high rates of successful implantation and reduction of mitral regurgitation symptoms in patients in global study - Device will be further studied in U.S.
Toggle Summary Five-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting Decisions
- Late-breaking data presented at EuroPCR and simultaneously published in "The New England Journal of Medicine" support use of Abbott's PressureWire™ guidewire to help physicians make stenting decisions - Stenting guided by Abbott's PressureWire diagnostic tool reduced major adverse coronary
Toggle Summary Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
- ADVISOR™ HD GRID MAPPING CATHETER, SENSOR ENABLED™ FACILITATES IMPROVED DATA COLLECTION, SUPPORTING OPTIMAL TREATMENT FOR PATIENTS WITH COMPLEX CARDIAC ARRHYTHMIAS - FIRST-OF-ITS-KIND GRID CONFIGURATION IS DESIGNED TO CAPTURE DATA IN MULTIPLE DIRECTIONS TO CREATE HIGH-DENSITY MAPS OF THE HEART -
Toggle Summary Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
- ADVISOR™ HD GRID MAPPING CATHETER, SENSOR ENABLED™ FACILITATES IMPROVED DATA COLLECTION, SUPPORTING OPTIMAL TREATMENT FOR PATIENTS WITH COMPLEX CARDIAC ARRHYTHMIAS - FIRST-OF-ITS-KIND GRID CONFIGURATION IS DESIGNED TO CAPTURE DATA IN MULTIPLE DIRECTIONS TO CREATE HIGH-DENSITY MAPS OF THE HEART -
Toggle Summary Abbott's XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease
- Provides patients with access to latest-generation gold-standard heart stent through Japan's health insurance system - XIENCE stents are among the most-widely used in the world, with unparalleled safety - New features help doctors more easily reach and treat difficult blockages in patients'
Toggle Summary Abbott's XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease
- Provides patients with access to latest-generation gold-standard heart stent through Japan's health insurance system - XIENCE stents are among the most-widely used in the world, with unparalleled safety - New features help doctors more easily reach and treat difficult blockages in patients'
Toggle Summary Sanquin Selects Abbott's "Alinity™ s" Solution for Blood and Plasma Screening
LONG-TERM AGREEMENT BETWEEN SANQUIN, A LEADER IN BLOOD SERVICES, AND ABBOTT, A GLOBAL LEADER IN TRANSFUSION MEDICINE, HELPS ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY IN THE NETHERLANDS AMSTERDAM , April 23, 2018 /PRNewswire/ -- Sanquin and Abbott (NYSE: ABT) announced today that they signed a
Toggle Summary Sanquin Selects Abbott's "Alinity™ s" Solution for Blood and Plasma Screening
LONG-TERM AGREEMENT BETWEEN SANQUIN, A LEADER IN BLOOD SERVICES, AND ABBOTT, A GLOBAL LEADER IN TRANSFUSION MEDICINE, HELPS ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY IN THE NETHERLANDS AMSTERDAM , April 23, 2018 /PRNewswire/ -- Sanquin and Abbott (NYSE: ABT) announced today that they signed a
Toggle Summary Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023
LONDON , April 20, 2018 /PRNewswire/ --  Abbott (NYSE: ABT) and the World Marathon Majors today announced the renewal of Abbott's title sponsorship. The partnership will extend into 2023, with the new four-year agreement beginning in 2019. Abbott became the first title sponsor of the series in
alt_text